A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

NCT05526222 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

443

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Jaktinib Hydrochloride Tablet

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd